| 0.3351 0.002 (0.63%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.46 | 1-year : | 0.53 |
| Resists | First : | 0.39 | Second : | 0.46 |
| Pivot price | 0.36  |
|||
| Supports | First : | 0.3 | Second : | 0.24 |
| MAs | MA(5) : | 0.33 |
MA(20) : | 0.37 |
| MA(100) : | 0.41 |
MA(250) : | 0.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.4 |
D(3) : | 24.2 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 1.09 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLNN ] has closed above bottom band by 27.9%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.32 - 0.32 | 0.32 - 0.33 |
| Close: | 0.33 - 0.34 | 0.34 - 0.34 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Tue, 16 Apr 2024
Clene stock rallies 52% post-market on MS drug data (NASDAQ:CLNN) - Seeking Alpha
Tue, 16 Apr 2024
Clene Inc. insider sells shares worth over $8600 - Investing.com India
Tue, 19 Mar 2024
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington - GlobeNewswire
Thu, 14 Mar 2024
Clene Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Wed, 13 Mar 2024
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 06 Mar 2024
Insiders Re-Evaluate Their US$9.58m Stock Purchase As Clene Falls To US$49m - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 6.677e+007 (%) |
| Held by Institutions | 40.1 (%) |
| Shares Short | 427 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.884e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 841.1 % |
| Return on Equity (ttm) | -52.4 % |
| Qtrly Rev. Growth | 654000 % |
| Gross Profit (p.s.) | -55.92 |
| Sales Per Share | -1215.25 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.64 |
| Dividend | 0 |
| Forward Dividend | 162890 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|